Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 173, Issue 4, 2006, Pages 421-425

  Kalish, Leslie A ^b   Waltz, David A ^b   Dovey, Mark ^b   Potter Bynoe, Gail ^b   McAdam, Alexander J ^b   LiPuma, John J ^b   Gerard, Craig ^b   Goldmann, Donald ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

Burkholderia cepacia complex; Burkholderia multivorans; Infection control

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BURKHOLDERIA; BURKHOLDERIA DOLOSA; BURKHOLDERIA MULTIVORANS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG FUNCTION; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; SEX RATIO;

ADULT; BURKHOLDERIA INFECTIONS; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE;

EID: 32444437595     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200503-344OC     Document Type: Article

References (34)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
2. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-1017.
3. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
4. Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, Strandvik B, McKenzie SG. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2001;18:298-305.
5. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104:206-210.
6. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Larson JM. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107:382-387.
7. Tablan OC, Martone WJ, Doershuk CF, Stern RC, Thomassen MJ, Klinger JD, White JW, Carson LA, Jarvis WR. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcomes. Chest 1987;91:527-532.
8. Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR, Evans TJ, Paton JY. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995;50:1194-1198.
9. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AG, Wittmann R, Wilcox PG. Burkholderia cepacia in cystic fibrosis: variable disease course. Am J Respir Crit Care Med 1999;160:1572-1577.
10. Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002;57:142-145.
11. Fitzgerald DA, Cooper DM, Paul M, Tiley S, Kado J, Cordwell J, Collins C. Burkholderia cepacia in cystic fibrosis: novel Australian cluster strain without accelerated respiratory deterioration. J Paediatr Child Health 2001;37:130-136.
12. Pegues DA, Carson LA, Tablan OC, FitzSimmons SC, Roman SB, Miller JM, Jarvis WR. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr 1994;124:694-702.
13. Sun L, Jiang RZ, Steinbach S, Holmes A, Campanelli C, Forstner J, Sajjan U, Tan Y, Riley M, Goldstein R. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995;1:661-666.
14. Chen JS, Witzmann KA, Spilker T, Fink RJ. LiPuma JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001;139:643-649.
15. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003;31:S1-62.
16. Govan JR, Hughes JE, Vandamme P. Burkholderia cepacia: medical, taxonomic and ecological issues. J Med Microbiol 1996;45:395-407.
17. Lipuma JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med 2003;24:681-692.
18. LiPuma JJ. Spilker T, Gill LH, Campbell PW III, Liu L,Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-96.
19. Jones AM, Dodd ME, Govan JR, Barcus V, Doherty CJ, Morris J, Webb AK. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004;59:948-951.
20. Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol 1999;37:2201-2208.
21. Blackburn L, Brownlee K, Conway S, Denton M. "Cepacia syndrome" with Burkholderia multivorans, 9 years after initial colonization. J Cyst Fibros 2004;3:133-134.
22. Coenye T, LiPuma JJ, Henry D, Hoste B, Vandemeulebroecke K, Gillis M, Speert DP, Vandamme P. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol 2001;51(Pt 2):271-279.
23. Vermis K, Coenye T. LiPuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 2004;54:689-691.
24. Henry DA, Campbell ME. LiPuma JJ, Speert DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997;35:614-619.
25. Biddick R, Spilker T, Martin A. LiPuma JJ. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003;228:57-62.
26. Knudson R, Lebowitz M, Holberg C, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:1721-1732.
27. Aris RM, Routh JC. LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-2106.
28. LiPuma JJ. Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990;336:1094-1096.
29. Lipuma JJ, Marks-Austin KA, Holsclaw DS Jr, Winnie GB, Gilligan PH, Stull TL. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994;13:716-719.
30. Davies J, Neth O, Alton E, Klein N, Turner M. Differential binding of mannose-binding lectin to respiratory pathogens in cystic fibrosis. Lancet 2000;355:1885-1886.
31. Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 1998;53:432-436.
32. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B, Speert DP. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-1475.
33. Bernhardt SA, Spilker T, Coffey T. LiPuma JJ. Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin Infect Dis 2003;37:780-785.
34. LiPuma JJ. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med 1998;4:337-341.